SOURCE: Amazon Biotech, Inc

February 16, 2007 16:15 ET

Amazon Biotech, Inc. Announces Issuance of Patent for a Unique Formulation and Method of Treating HIV Infection

NEW YORK, NY -- (MARKET WIRE) -- February 16, 2007 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) announced that it has been issued a patent from the United States Patent and Trademark Office, patent # 7,160,561 for "a herbal composition and method of treating HIV infection."

AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:
    LC Group
    Rick Lutz
    (404) 261-1196